

Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function

Christianne L. Roumie, MD, MPH; Jonathan Chipman, PhD; Jea Young Min, PharmD, MPH, PhD; Amber J. Hackstadt, PhD; Adriana M. Hung, MD, MPH; Robert A. Greevy Jr, PhD; Carlos G. Grijalva, MD, MPH; Tom Elasy, MD, MPH; Marie R. Griffin, MD, MPH

IMPORTANCE Before 2016, safety concerns limited metformin use in patients with kidney disease; however, the effectiveness of metformin on clinical outcomes in patients with reduced kidney function remains unknown.

OBJECTIVE To compare major adverse cardiovascular events (MACE) among patients with diabetes and reduced kidney function who continued treatment with metformin or a sulfonylurea.

DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study of US veterans receiving care within the national Veterans Health Administration, with data supplemented by linkage to Medicare, Medicaid, and National Death Index data from 2001 through 2016. There were 174 882 persistent new users of metformin and sulfonylureas who reached a reduced kidney function threshold (estimated glomerular filtration rate <60 mL/min/1.73 m² or creatinine ≥1.4 mg/dL for women or ≥1.5 mg/dL for men). Patients were followed up from reduced kidney function threshold until MACE, treatment change, loss to follow-up, death, or study end (December 2016).

EXPOSURES New users of metformin or sulfonylurea monotherapy who continued treatment with their glucose-lowering medication after reaching reduced kidney function.

MAIN OUTCOMES AND MEASURES MACE included hospitalization for acute myocardial infarction, stroke, transient ischemic attack, or cardiovascular death. The analyses used propensity score weighting to compare the cause-specific hazard of MACE between treatments and estimate cumulative risk accounting for the competing risks of changing therapy or noncardiovascular death.

RESULTS There were 67 749 metformin and 28 976 sulfonylurea persistent monotherapy users; the weighted cohort included 24 679 metformin and 24 799 sulfonylurea users (median age, 70 years [interquartile range {IQR}, 62.8-77.8]; 48 497 men [98%]; and 40 476 white individuals [82%], with median estimated glomerular filtration rate of 55.8 mL/min/1.73 m² [IQR, 51.6-58.2] and hemoglobin A_{1c} level of 6.6% [IQR, 6.1%-7.2%] at cohort entry). During follow-up (median, 1.0 year for metformin vs 1.2 years for sulfonylurea), there were 1048 MACE outcomes (23.0 per 1000 person-years) among metformin users and 1394 events (29.2 per 1000 person-years) among sulfonylurea users. The cause-specific adjusted hazard ratio of MACE for metformin was 0.80 (95% CI, 0.75-0.86) compared with sulfonylureas, yielding an adjusted rate difference of 5.8 (95% CI, 4.1-7.3) fewer events per 1000 person-years of metformin use compared with sulfonylurea use.

CONCLUSIONS AND RELEVANCE Among patients with diabetes and reduced kidney function persisting with monotherapy, treatment with metformin, compared with a sulfonylurea, was associated with a lower risk of MACE.

JAMA. 2019;322(12):1167-1177. doi:10.1001/jama.2019.13206
Published online September 19, 2019.

← Editorial page 1147

← Related article page 1155

+ Supplemental content

Author Affiliations: Veteran Administration Tennessee Valley VA Health Care System Geriatric Research Education Clinical Center, Nashville (Roumie, Min, Hung, Grijalva, Elasy, Griffin); Department of Medicine, Vanderbilt University Medical Center, Nashville (Roumie, Hung, Elasy, Griffin); Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee (Chipman, Hackstadt, Greevy); Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee (Min, Grijalva, Griffin).

Corresponding Author: Christianne L. Roumie, MD, MPH, Nashville VA Medical Center, Geriatric Research Education Clinical Center, 1310 24th Ave S, Nashville, TN 37212 (christianne.roumie@vanderbilt.edu).

In 2012, there were approximately 30 million US adults diagnosed as having type 2 diabetes, of whom 20% also had impaired kidney function.¹ Metformin is the initial recommended diabetes treatment based on the beneficial results reported in 1998 from the UK Prospective Diabetes Study (UKPDS) 34.^{2,3} The UKPDS demonstrated that metformin reduced the incidence of macrovascular complications compared with sulfonylureas or insulin independent of glycemic control.^{2,4} Several large observational studies support the UKPDS findings.⁴⁻⁷

Metformin is eliminated by the kidneys and can accumulate as estimated glomerular filtration rate (eGFR) declines. Based on the negative clinical experience with phenformin and the potential for metformin-associated lactic acidosis, the US Food and Drug Administration (FDA) issued a safety warning restricting metformin for patients with serum creatinine levels of 1.5 mg/dL or greater for men or 1.4 mg/dL or greater for women.⁸ In 2016, the FDA changed its guidance based on evidence regarding metformin safety in patients with mild to moderate kidney disease; however, the effectiveness of metformin for clinical outcomes in those with reduced kidney function remains unknown. Large clinical trials that investigated diabetes treatment effects on cardiovascular outcomes excluded patients with reduced eGFR, rendering this population understudied.^{2,5,9-12}

The aim of this study was to test the hypothesis that among patients with diabetes who develop reduced kidney function, continued metformin use is associated with lower risk of fatal or nonfatal major adverse cardiovascular events (MACE) than sulfonylureas.

Methods

Study Design and Data Sources

We assembled a retrospective cohort of Veterans Health Administration (VHA) patients.⁴ Pharmacy data included medication, date filled, days supplied, and number of pills dispensed. Demographic, diagnostic, and procedure information identified inpatient and outpatient VHA encounters. We collected laboratory results and vital signs data from clinical sources. For Medicare or Medicaid enrollees, we obtained enrollment, claims files, and prescription (Part D) data for Medicare enrollees.^{13,14} We obtained dates and cause of death from vital status and the National Death Index files.^{15,16} The institutional review board of VHA Tennessee Valley Healthcare System approved this study with a waiver of informed consent.

Study Population

The source population comprised veterans aged 18 years and older who were regular users of the VHA care, defined as an encounter or prescription fill at least once every 365 days for 2 or more years prior to cohort entry. We identified patients with new-onset type 2 diabetes by selecting those who were new users of metformin, glipizide, glyburide, or glimepiride. New users were patients who filled a first glucose-lowering prescription without any diabetic drug fill in the 180 days prior to that first fill. We followed up these patients with diabetes

Key Points

Question Is there an association between treatment with metformin vs sulfonylureas and major adverse cardiovascular events (MACE) among patients with diabetes and reduced kidney function?

Findings In this retrospective cohort study of 49 478 patients with diabetes and reduced kidney function, the incidence of MACE for those treated with metformin vs sulfonylurea monotherapy was 23.0 per 1000 person-years vs 29.2 per 1000 person-years, a difference that was statistically significant.

Meaning Monotherapy treatment with metformin, compared with a sulfonylurea, was associated with a lower risk of MACE among patients with diabetes and reduced kidney function.

longitudinally and selected patients who experienced a decline in kidney function. Patients were required to persist with their initial monotherapy with no medication gaps for more than 180 days or medication switching prior to reaching the kidney threshold to be eligible for cohort entry.

The date of cohort entry and start of follow-up was the day of reaching a reduced kidney function threshold (eFigure 1 in the Supplement), defined as either an eGFR of less than 60 mL/min/1.73 m² or serum creatinine level of 1.5 mg/dL for men or 1.4 mg/dL for women. Cohort entry was between January 1, 2002, and December 30, 2015, to allow sufficient collection of baseline data and follow-up. We excluded patients who added or switched glucose-lowering medications at or prior to the kidney threshold or had 2 or more episodes of dialysis, organ transplantation, or hospice care within the 2 years prior to reaching the kidney threshold.

Exposure

The study exposures were persistent use of metformin or a sulfonylurea (glyburide, glipizide, and glimepiride) after reaching the kidney threshold. Follow-up began on the date the kidney threshold (eGFR <60 mL/min/1.73 m² or serum creatinine level, 1.4/1.5 mg/dL) was fulfilled and continued through an outcome (below); nonpersistence, defined as 90 days without an antidiabetic drug or the addition of or switch to a different glucose-lowering drug; censoring, defined as the 181st day of no VHA contact (inpatient, outpatient, or pharmacy use); noncardiovascular death; or study end (December 31, 2016). Seventy percent of the population received 90-day prescriptions and, in this population, allowing 90 days to refill medications approximates 80% adherence.¹⁷

Outcomes

The composite outcome was MACE including hospitalization for acute myocardial infarction (AMI), ischemic or hemorrhagic stroke, transient ischemic attack (TIA), or date of cardiovascular death. The outcome date was the date of hospital admission for AMI, stroke, or TIA or the date of cardiovascular death. The primary discharge diagnosis, either *International Classification of Diseases, Ninth Revision, Clinical Modification (ICD9-CM)* or *ICD-10* codes before or after October 1, 2015, respectively, was used to identify outcomes.

We defined AMI by codes 410.x or I21.x. Stroke hospitalizations encompassed those with an ischemic stroke (433.x1, 434 [excluding 434.x0], and 436 or I63.30, I63.40, I63.50, I66.09, I66.19, I66.29, I66.9, I67.848, and I67.89), intracerebral hemorrhage (431 or I61.x), and subarachnoid hemorrhage (430 or I60.x). TIA hospitalizations were defined by codes 435 or G45.0, G45.1, G45.8, or G45.9. Medical record review and validation of a sample of these codes have shown high specificity and positive predictive values of 90% for AMI and 81% for stroke when compared with VHA medical record review.¹⁸

Cardiovascular deaths were identified from death certificates with an *ICD-10* underlying cause of death compatible with cardiac death, fatal myocardial infarction, stroke, or cardiomyopathy (I00-I78 excluding I30.X [diseases of the pericardium]) or unattended sudden cardiac death (R98, R99, R960, and R961). This definition included the Centers for Disease Control and Prevention's broad definition of cardiac death and a validated strategy for identification of sudden cardiac deaths.¹⁹

The secondary outcome excluded TIA as part of the composite MACE event. Because not all patients who sustain a TIA are admitted to the hospital, we determined whether the addition of TIA emergency department visits that did not lead to hospital admission would influence the outcome event rates. TIA emergency department visits included the above codes for TIA in the primary (first listed) diagnosis position of outpatient emergency department visits.

Covariates

Study covariates were measured up to 720 days before the reduced kidney function threshold and included age, sex, race, fiscal year, number of months from initial antidiabetic medication to kidney threshold (diabetes duration), and Veterans Integrated Service Networks (VISN) of care. Each VISN of care is a geographic designation for VHA and allowed a more granular estimation of geographic variation of diabetes care. Physiologic variables were defined as the most recent measure prior to kidney threshold and included body mass index (calculated as weight in kilograms divided by height in meters squared), blood pressure, hemoglobin A_{1c} (HbA_{1c}), low-density lipoprotein, hemoglobin, proteinuria, and creatinine values (both historical and the creatinine at cohort entry).

Creatinine was used to calculate eGFR using the Chronic Kidney Disease Epidemiology Collaboration equation.^{20,21} The Isotope Dilution Mass Spectroscopy calibration date was collected and accounted for in estimation of eGFR for 70% of the VHA facilities. Facilities where no Isotope Dilution Mass Spectroscopy switch date was identified had all eGFRs downward adjusted by 5%.²² Health care utilization (hospitalization, nursing home, number of outpatient visits or medications, and Medicare or Medicaid insurance use) was measured in the year prior to the reduced kidney function threshold. We collected data on smoking and comorbidities as defined in eTable 1 in the [Supplement](#). Selected medications filled within 180 days prior to the reduced kidney function threshold were also covariates. Because race is associated with cardiovascular outcomes, it was included in all models. We selected patient self-reported categorical race from VHA data and supplemented

with Medicare patient self-reported categorical race data to minimize missing values.

Statistical Analyses


The primary analysis compared the cause-specific hazard of MACE between medication groups in a propensity score-weighted cohort. The propensity score modeled the probability of metformin or sulfonylurea continuation at reduced kidney function threshold given covariates, VISN, and an indicator for imputed covariates. Missing covariates were handled using 20 iterations of chained imputations and adjusting for canonical variates.²³ We used matching weights to balance both exposure groups on observed covariates (detailed methods in eTable 2 and eFigures 2-4 in the [Supplement](#)).^{24,25} Standardized mean differences are the absolute value of the difference in means or proportions divided by a pooled standard deviation. Standardized mean differences were calculated as the difference between groups in number of standard deviations and is a more meaningful measure than *P* values from *t* tests for large samples.

Cox proportional hazards models estimated the cause-specific hazard ratios (HRs) for metformin vs sulfonylurea (referent) in the weighted cohort, adjusted for covariates. Statistical significance for the 2-sided *P* value was set at .05. The proportional hazards assumptions were verified through examination of Schoenfeld residuals over time.²⁶ The cause-specific hazard allowed estimation of the medication association with MACE in those patients who were event free.²⁷ Nonparametric estimates of the cumulative incidence of MACE accounted for 2 competing risks: medication nonpersistence and noncardiovascular death. Cumulative incidence curves were generated using the Aalen-Johansen estimator. The nonparametric Aalen-Johansen estimator was preferred over the semiparametric Fine and Gray model because it allowed more flexibility when modeling the cumulative incidence function.^{28,29}

Sensitivity and Subgroup Analyses

The first sensitivity analysis evaluated a cohort with chronic kidney disease and required patients to have a second measured eGFR less than 60 mL/min/1.73 m² between 30 and 180 days after the first eGFR less than 60 mL/min/1.73 m² and began cohort entry at 180 days from the first eGFR less than 60 mL/min/1.73 m². The second sensitivity analysis assumed patients remained in their initial exposure groups and did not censor follow-up based on regimen changes or the 90-day refill requirement (ie, persistent exposure was not required). This analysis is akin to an intention-to-treat analysis in clinical trials and increases follow-up time and events but allows exposure time misclassification (eFigure 1 in the [Supplement](#)). A third sensitivity analysis excluded patients who were enrolled in Medicare Advantage at baseline and censored patients at Medicare Advantage enrollment to determine whether results were influenced by Advantage status. Subgroup analyses tested for effect modification by including interaction terms (treatment by subgroup) in the model for the following groups: history of cardiovascular disease (yes, no), age (≥ 65 years, < 65 years), race (black, nonblack), baseline eGFR (45-59, 30-45, or < 30 mL/min/1.73 m²), and if the patient entered the cohort

Figure 1. Eligible Patients in the Veterans Health Administration



based on reaching the FDA creatinine threshold or a reduced eGFR with a serum creatinine less than the FDA threshold. Analyses were conducted using R (<http://www.r-project.org>).

Results

Study Cohort and Patient Characteristics

We identified 67 749 new metformin users and 28 976 new sulfonylurea users who persisted with treatment, met the reduced kidney function threshold, and satisfied cohort entry criteria (Figure 1). These cohort patients represent 55.3% of the 174 882 new persistent users who had a baseline creatinine level and reached the reduced kidney function threshold. We excluded 49 755 who added another diabetes medication on or before the kidney threshold, 18 651 who met the kidney threshold outside the study time frame, 9184 who had no supply of metformin or sulfonylurea in the 90 days before reaching the kidney threshold, and those with organ transplant ($n = 206$), hospice care ($n = 219$), dialysis use in the past 2 years ($n = 25$), or data error ($n = 117$). The weighted cohort included 24 679 metformin users and 24 799 sulfonylurea users (54% glipizide, 45% glyburide, and 1% glimepiride).

Cohort patients were 98% male and 81.8% white. Metformin users were younger than sulfonylurea users (median age, 67 vs 71 years; eFigure 3 in the Supplement) and a larger proportion of metformin users reached the kidney threshold in later study years.^{30,31} HbA_{1c} (6.6% [interquartile range {IQR}, 6.1-7.2]; 49 mmol/mol [IQR, 43-55]), eGFR at cohort entry (55.8 mL/min/1.73 m² [IQR, 51.6-58.2]), and historical eGFR before cohort entry (69.6 mL/min/1.73 m² [IQR, 64.7-77.0]) were similar between exposures. Standardized mean differences were less than 0.10 after weighting (Table 1).

Median follow-up in the weighted cohort was 1.0 year (IQR, 0.4-2.6) for patients taking metformin and 1.2 years (IQR, 0.5-2.7) for sulfonylurea users. At 3 years of follow-up, 84.7% vs 82.4% metformin and sulfonylurea users, respectively, had stopped or switched treatment; 3.0% vs 4.1% had experienced noncardiovascular death; 2.5% vs 3.3% were censored for leaving the VHA; and 5.6% vs 4.7% reached study end.

MACE Outcomes

After propensity score weighting, there were 1048 composite events among metformin patients with reduced kidney function and 1394 events among sulfonylurea patients, yielding 23.0 (95% CI, 21.7-24.4) vs 29.2 (95% CI, 27.7-30.7) events per 1000 person-years of use, respectively. After covariate adjustment, the cause-specific adjusted HR (aHR) for MACE was 0.80 (95% CI, 0.75-0.86) among metformin users compared with sulfonylurea. The adjusted incident rate difference was 5.8 (95% CI, 4.1-7.3) fewer events per 1000-person years for metformin compared with sulfonylurea users. The cumulative probability of MACE for patients in the metformin group vs the sulfonylurea group was 1.9% vs 2.5% at 1 year, 3.4% vs 4.4% at 3 years, and 3.8% vs 4.9% at 4 years (Figure 2).

Results were consistent for each component of the primary outcome, including cardiovascular hospitalizations (aHR, 0.87 [95% CI, 0.80-0.95]) and cardiovascular deaths (aHR, 0.70 [95% CI, 0.63-0.78]) (Table 2). eFigure 5 in the Supplement demonstrates the cumulative incidence of MACE accounting for the competing risks of medication nonpersistence and noncardiovascular death. The secondary outcome, which included AMI, stroke, and cardiovascular death and excluded TIA, demonstrated consistent results (Table 2). Addition of TIA emergency department visits added 10 events in the weighted cohort (5 each for metformin and sulfonylurea users) and the estimates were unchanged.

Table 1. Characteristics of Patients at the Time They Reached a Reduced Kidney Function Threshold

Characteristic	Full Unweighted Cohort			Propensity Score-Weighted Cohort		
	Metformin (n = 67 749)	Sulfonylurea (n = 28 976)	SMD ^a	Metformin (n = 24 679)	Sulfonylurea (n = 24 799)	SMD ^a
Patient Characteristics						
Age, median (IQR), y	67.3 (62.1-74.4)	71.1 (63.2-78.8)	0.28	70.1 (62.9-77.8)	70.0 (62.8-77.8)	0.001
Sex, No. (%)						
Male	64921 (95.8)	28459 (98.2)	0.14	24189 (98.0)	24308 (98.0)	<0.001
Female	2828 (4.2)	517 (1.8)		490 (2.0)	491 (1.9)	
Race, No. (%) ^b						
White	56392 (83.2)	23524 (81.2)	0.07	20186 (81.8)	20290 (81.8)	0.001
Black	9883 (14.6)	4924 (17.0)		4035 (16.4)	4047 (16.3)	
Other	1474 (2.2)	528 (1.8)		458 (1.9)	462 (1.9)	
Medication start to kidney threshold (diabetes duration), median (IQR), mo	16.2 (6.5-35.1)	13.6 (5.9-29.0)	0.15	14.0 (5.8-30.2)	14.0 (6.0-30.3)	0.01
Year reduced kidney threshold was reached, No. (%)						
2002-2003	3167 (4.7)	4904 (16.9)	0.76	2924 (11.8)	2918 (11.3)	0.03
2004-2005	5786 (8.5)	5737 (19.8)		4479 (18.2)	4442 (17.2)	
2006-2007	9075 (13.4)	6101 (21.1)		5207 (21.1)	5437 (21.1)	
2008-2009	9952 (14.7)	4051 (14.0)		3876 (15.7)	3895 (15.1)	
2010-2011	12237 (18.1)	3341 (11.5)		3367 (13.6)	3289 (12.7)	
2012-2013	12854 (18.9)	2619 (9.0)		2651 (10.7)	2600 (10.1)	
2014-2015	14678 (21.7)	2223 (7.7)		2175 (8.8)	2218 (8.6)	
Laboratory Variables						
Hemoglobin A _{1c} , median (IQR), %	6.5 (6.1-7.0)	6.6 (6.1-7.3)	0.15	6.5 (6.1-7.1)	6.6 (6.1-7.2)	0.005
No. with available measure	64981	27838		23668	23805	
Creatinine at kidney threshold, median (IQR), mg/dL	1.33 (1.24-1.43)	1.33 (1.24-1.43)	0.05	1.33 (1.24-1.43)	1.33 (1.24-1.43)	0.002
Estimated glomerular filtration rate, median (IQR), mL/min/1.73 m ²						
Before kidney threshold	70.5 (65.1-78.6)	69.3 (64.5-76.6)	0.13	69.6 (64.6-77.0)	69.7 (64.7-77.0)	0.001
At kidney threshold	55.9 (51.6-58.3)	55.8 (51.5-58.2)	0.02	55.8 (51.6-58.2)	55.8 (51.6-58.2)	0.002
Hemoglobin, median (IQR), g/L	14.0 (12.9-15.0)	14.1 (13.0-15.2)	0.05	14.1 (13.0-15.1)	14.1 (13.0-15.2)	0.002
No. with available measure	64119	27264		23167	23292	
Low-density lipoprotein cholesterol, median (IQR), mg/dL	85 (67-106)	89 (72-111)	0.13	88 (70-110)	88 (71-110)	0.002
No. with available measure	66426	27837		23883	24002	
Microalbumin to creatinine ratio stage, No. (%) with available measure	38 869	14632		12913	12969	
A1 (<30 mg/g: normal to mild increase albuminuria)	29656 (43.8)	10625 (36.7)	0.16	9470 (38.4)	9530 (38.4)	0.003
A2 (30-300 mg/g: moderate increase albuminuria)	7398 (10.9)	3076 (10.6)		2674 (10.8)	2676 (10.8)	
A3 and positive unable to quantify (>300 mg/g: severely increased albuminuria)	1815 (2.7)	931 (3.2)		769 (3.1)	763 (3.1)	
Proteinuria by urinalysis, No. (%) with available measure	45852	19167		16372	16466	
Negative	32963 (48.7)	13516 (46.7)	0.08	11648 (47.2)	11704 (47.2)	0.002
Urine protein trace or 1+	10071 (14.9)	4185 (14.4)		3574 (14.5)	3606 (14.5)	
Proteinuria present at 2+	2186 (3.2)	983 (3.4)		803 (3.3)	809 (3.3)	
Proteinuria present at 3+ or 4+	632 (0.9)	483 (1.7)		347 (1.4)	348 (1.4)	
Clinical Variables						
Blood pressure, median (IQR), mm Hg						
Systolic	129 (117-139)	130 (119-142)	0.12	131 (119-142)	131 (119-142)	0.002
Diastolic	73 (65-80)	71 (64-80)	0.10	72 (64-80)	72 (64-80)	<0.001
Body mass index, median (IQR) ^c	31.1 (27.7-35.2)	30.1 (26.9-34.1)	0.16	30.4 (27.1-34.4)	30.3 (27.1-34.3)	0.005
No. with available measure	56235	23243		20070	20163	

(continued)

Table 1. Characteristics of Patients at the Time They Reached a Reduced Kidney Function Threshold (continued)

Characteristic	Full Unweighted Cohort			Propensity Score–Weighted Cohort		
	Metformin (n = 67 749)	Sulfonylurea (n = 28 976)	SMD ^a	Metformin (n = 24 679)	Sulfonylurea (n = 24 799)	SMD ^a
Baseline Comorbidities, No.(%)^d						
Cardiovascular/diabetes complications						
Cardiovascular disease	17700 (26.1)	9811 (33.9)	0.17	7797 (31.6)	7868 (31.7)	0.003
Arrhythmia	9510 (14.0)	5469 (18.9)	0.13	4289 (17.4)	4320 (17.4)	0.001
Congestive heart failure	5526 (8.2)	4218 (14.6)	0.20	2987 (12.1)	3009 (12.1)	0.001
Cardiac valve disease	1894 (2.8)	1196 (4.1)	0.07	897 (3.6)	907 (3.7)	0.001
Stroke	1900 (2.8)	1030 (3.6)	0.04	832 (3.4)	830 (3.3)	0.001
Transient ischemic attack	710 (1.0)	410 (1.4)	0.03	321 (1.3)	331 (1.3)	0.003
Retinopathy	508 (0.7)	399 (1.4)	0.06	290 (1.2)	291 (1.2)	<0.001
Amputation	230 (0.3)	170 (0.6)	0.04	116 (0.5)	120 (0.5)	0.002
Pulmonary						
Chronic obstructive pulmonary disease	10303 (15.2)	5266 (18.2)	0.08	4196 (17.0)	4234 (17.1)	0.002
Smoking	8749 (12.9)	3551 (12.3)	0.02	3062 (12.4)	3085 (12.4)	0.001
History of respiratory failure	1967 (2.9)	963 (3.3)	0.02	792 (3.2)	792 (3.2)	0.001
History of pneumonia	2179 (3.2)	1426 (4.9)	0.09	1056 (4.3)	1074 (4.3)	0.003
Neurologic/psychiatric						
Serious mental illness	16588 (24.5)	5825 (20.1)	0.11	5046 (20.4)	5121 (20.6)	0.005
Parkinson disease	496 (0.7)	310 (1.1)	0.04	228 (0.9)	231 (0.9)	0.001
Infectious						
Urinary tract infection	2267 (3.3)	1375 (4.7)	0.07	1035 (4.2)	1046 (4.2)	0.001
History of sepsis	961 (1.4)	511 (1.8)	0.03	397 (1.6)	403 (1.6)	0.001
Osteomyelitis	309 (0.5)	198 (0.7)	0.03	155 (0.6)	153 (0.6)	0.002
HIV	235 (0.3)	118 (0.4)	0.01	95 (0.4)	97 (0.4)	0.001
Oncologic/metabolic comorbidity						
Malignancy	7199 (10.6)	3514 (12.1)	0.05	2892 (11.7)	2909 (11.7)	<0.001
Liver disease	1131 (1.7)	820 (2.8)	0.08	596 (2.4)	593 (2.4)	0.002
History of kidney disease	73 (0.1)	52 (0.2)	0.02	35 (0.1)	38 (0.2)	0.002
Markers of frailty						
Osteoporosis	475 (0.7)	239 (0.8)	0.01	196 (0.8)	202 (0.8)	0.002
Falls	147 (0.2)	73 (0.3)	0.007	55 (0.2)	57 (0.2)	0.001
Fractures	1257 (1.9)	679 (2.3)	0.03	549 (2.2)	549 (2.2)	0.001
Use of Medications, No. (%)						
Angiotensin-converting enzyme inhibitors	43222 (63.8)	18809 (64.9)	0.02	15963 (64.7)	16087 (64.9)	0.004
β-Blockers	33337 (49.2)	14797 (51.1)	0.04	12511 (50.7)	12585 (50.7)	0.001
Thiazide and potassium-sparing diuretics	29980 (44.3)	11572 (39.9)	0.09	10101 (40.9)	10194 (41.1)	0.004
Calcium channel blockers	19720 (29.1)	8665 (29.9)	0.02	7379 (29.9)	7412 (29.9)	<0.001
Loop diuretics	10315 (15.2)	6621 (22.8)	0.20	4956 (20.1)	4983 (20.1)	<0.001
Angiotensin II receptor blockers	8697 (12.8)	3109 (10.7)	0.07	2816 (11.4)	2807 (11.3)	0.003
Other antihypertensive medications	18458 (27.2)	7831 (27.0)	0.005	6715 (27.2)	6726 (27.1)	0.002
Statin lipid-lowering drugs	49906 (73.7)	18670 (64.4)	0.20	16545 (67.0)	16695 (67.3)	0.006
Nonstatin lipid-lowering agents	13166 (19.4)	4665 (16.1)	0.09	4244 (17.2)	4272 (17.2)	0.001
Antiarrhythmics digoxin and inotropes	4395 (6.5)	3143 (10.8)	0.16	2260 (9.2)	2272 (9.2)	<0.001
Anticoagulants	6027 (8.9)	3099 (10.7)	0.06	2488 (10.1)	2495 (10.1)	0.001
Nitrates	7812 (11.5)	4715 (16.3)	0.14	3628 (14.7)	3664 (14.8)	0.002
Aspirin	14371 (21.2)	6542 (22.6)	0.03	5359 (21.7)	5407 (21.8)	0.002
Platelet inhibitors, not aspirin	6240 (9.2)	3100 (10.7)	0.05	2574 (10.4)	2591 (10.4)	0.001
Antipsychotics	5414 (8.0)	1992 (6.9)	0.04	1740 (7.0)	1762 (7.1)	0.002
Oral glucocorticoids	5050 (7.5)	2139 (7.4)	0.003	1795 (7.3)	1812 (7.3)	0.001

(continued)

Table 1. Characteristics of Patients at the Time They Reached a Reduced Kidney Function Threshold (continued)

Characteristic	Full Unweighted Cohort			Propensity Score–Weighted Cohort		
	Metformin (n = 67 749)	Sulfonyleurea (n = 28 976)	SMD ^a	Metformin (n = 24 679)	Sulfonyleurea (n = 24 799)	SMD ^a
Indicators of Health Care Utilization						
Hospitalized within year, No. (%)						
With claim in Veterans Health	9076 (13.4)	4516 (15.6)	0.06	3574 (14.5)	3630 (14.6)	0.004
With claim in Medicare/Medicaid	5634 (8.3)	3597 (12.4)	0.16	2770 (11.2)	2789 (11.2)	0.001
Hospitalized in 30 d, No. (%)						
With claim in Veterans Health	2510 (3.7)	1197 (4.1)	0.02	942 (3.8)	962 (3.9)	0.003
With claim in Medicare/Medicaid	987 (1.5)	581 (2.0)	0.04	440 (1.8)	452 (1.8)	0.003
Nursing home encounter in last year, No. (%)	201 (0.3)	136 (0.5)	0.03	96 (0.4)	100 (0.4)	0.002
No. of medications, median (IQR)	7 (5-11)	7 (4-10)	0.06	7 (4-10)	7 (4-10)	0.003
Outpatient visits in past year, median (IQR)	6 (3-11)	7 (4-12)	0.05	6 (4-11)	6 (4-11)	0.002
Insurance use, No. (%)						
Medicare in last year	21435 (31.6)	10538 (36.4)	0.10	8807 (35.7)	8812 (35.5)	0.003
Medicaid in last year	663 (1.0)	435 (1.5)	0.05	323 (1.3)	331 (1.3)	0.002
Medicare Advantage	10251 (15.1)	4339 (15.0)	0.004	3770 (15.3)	3784 (15.3)	0.001

Abbreviations: IQR, interquartile range; SMD, standardized mean difference.

SI conversion factors: to convert creatinine to $\mu\text{mol/L}$, multiply by 88.4; low-density lipoprotein cholesterol to mmol/L , multiply by 0.0259.

^a SMDs are the absolute difference in means or percentage divided by an evenly weighted pooled standard deviation, or the difference between groups in number of standard deviations. In the weighted cohort, all standardized differences were less than 0.01, suggesting there were no important

imbalances (see eFigure 3 in the Supplement for the plot of the mean standardized differences of the preweighted and weighted cohort).

^b Other races include American Indian or Alaska Native, Asian, and Native Hawaiian or other Pacific Islander.

^c Calculated as weight in kilograms divided by height in meters squared.

^d Definitions of comorbidities are listed in eTable 1 in the Supplement.


Sensitivity and Subgroup Analyses

Among the 14 589 patients who had a second confirmatory eGFR less than 60 mL/min/1.73 m² and remained persistent with their regimen, the median number of days to the second confirmatory eGFR was 112 days (IQR, 73-147). Among this chronic kidney disease cohort, there were 3586 weighted metformin users and 4287 weighted sulfonyleurea users, and results were similar but no longer statistically significant for the primary MACE outcome. However, results reached statistical significance for the outcome of cardiovascular death. After removing the requirement for glucose-lowering medication persistence and excluding Medicare Advantage patients, all results were consistent (Table 2). Subgroup analyses stratified by history of cardiovascular disease, age, race, eGFR at kidney threshold, and if the patient entered via reaching the FDA-defined elevated creatinine or reduced eGFR threshold with creatinine below the FDA guidance were consistent with the main analysis, with no evidence of effect modification (all *P* values >.20). For smaller subgroups, HR confidence intervals were wide (Figure 3 and eTable 3 in the Supplement).

Discussion

Among patients with diabetes who developed reduced kidney function, persistent use of metformin compared with sulfonyleurea use was associated with a decreased hazard of MACE. This study and the results add to the limited observational evidence for the beneficial association of metformin compared with sulfonyleurea and cardiovascular outcomes among those who develop reduced kidney function.³²

Figure 2. Competing Risk Cumulative Incidence Match-Weighted Cohort



Aalen-Johansen cumulative probability of incident major adverse cardiovascular events (MACE) among sulfonyleurea vs metformin cohort with reduced kidney function. The median follow-up time in the weighted cohort was 1.0 year (interquartile range, 0.4-2.6) for patients taking metformin and 1.2 years (interquartile range, 0.5-2.7) for sulfonyleurea users.

Although there is consensus that metformin is first-line diabetes treatment, metformin is discontinued in many patients when kidney disease develops. Flory and Hennessy³³ reported that nearly 1 million US patients with diabetes and eGFR between 31 and 89 mL/min/1.73 m² could take metformin but do not. In April 2016, the FDA issued a safety announcement and revised label regarding metformin use in patients with reduced kidney function.³⁴ The revised label states that

Table 2. Rates and Adjusted Hazard Ratios for Major Adverse Cardiovascular Events (MACE) in Weighted Cohort

	Metformin	Sulfonylurea
Persistent Exposure Required^a		
No. at risk in weighted cohort	24 679	24 799
Primary outcome: composite MACE	1048	1394
Person-years	45542	47762
Unadjusted rate/1000 person-years (95% CI)	23.0 (21.7 to 24.4)	29.2 (27.7 to 30.7)
Adjusted hazard ratio (95% CI) ^b	0.80 (0.75 to 0.86)	1 [Reference]
Adjusted incident rate difference (95% CI) ^c		-5.8 (-7.3 to -4.1)
Component of primary outcome: cardiovascular hospitalization (AMI, stroke, or TIA)	708	874
Unadjusted rate/1000 person-years (95% CI)	15.5 (14.4 to 16.7)	18.3 (17.1 to 19.5)
Adjusted hazard ratio (95% CI) ^b	0.87 (0.80 to 0.95)	1 [Reference]
Adjusted incident rate difference (95% CI) ^c		-2.4 (-3.7 to -0.9)
Component of primary outcome: cardiovascular death	407	623
Person-years	46 484	49 066
Unadjusted rate/1000 person-years (95% CI)	8.8 (8.0 to 9.6)	12.7 (11.7 to 13.7)
Adjusted hazard ratio (95% CI) ^b	0.70 (0.63 to 0.78)	1 [Reference]
Adjusted incident rate difference (95% CI) ^c		-3.8 (-4.7 to -2.8)
Secondary outcome: AMI, stroke, or cardiovascular death	953	1297
Person-years	45719	47987
Unadjusted rate/1000 person-years (95% CI)	20.8 (19.6 to 22.2)	27.0 (25.6 to 28.5)
Adjusted hazard ratio (95% CI) ^b	0.78 (0.72 to 0.84)	1 [Reference]
Adjusted incident rate difference (95% CI) ^c		-5.9 (-7.6 to -4.3)
Sensitivity Analysis: Population With 2 Reduced eGFRs Who Remain Persistent With Medication		
No. at risk in weighted cohort	3586	4287
Primary outcome: composite MACE	160	273
Person-years	6676	8797
Unadjusted rate/1000 person-years (95% CI)	24.0 (20.6 to 27.9)	31.0 (27.6 to 34.9)
Adjusted hazard ratio (95% CI) ^b	0.85 (0.70 to 1.02)	1 [Reference]
Adjusted incident rate difference (95% CI) ^c		-4.7 (-9.3 to 0.6)
Component of primary outcome: cardiovascular hospitalization (AMI, stroke, or TIA)	103	162
Person-years	6676	8797
Unadjusted rate/1000 person-years (95% CI)	15.4 (12.7 to 18.7)	18.4 (15.8 to 21.4)
Adjusted risk difference (95% CI)		-1.7 (-5.2 to 2.6)
Adjusted hazard ratio (95% CI) ^b	0.91 (0.72 to 1.15)	1 [Reference]
Component of primary outcome: cardiovascular death	67	134
Person years	6809	8980
Unadjusted rate/1000 person-years (95% CI)	9.8 (7.7 to 12.4)	15.0 (12.6 to 17.7)
Adjusted risk difference (95% CI)		-4.4 (-7.1 to -1.1)
Adjusted hazard ratio (95% CI) ^b	0.71 (0.53 to 0.93)	1 [Reference]
Sensitivity Analysis: Persistent Exposure Not Required^d		
No. at risk in weighted cohort	24 679	24 799
Primary outcome: composite MACE	4479	4722
Person-years	153 840	148 115
Unadjusted rate/1000 person-years (95% CI)	29.1 (28.2 to 30.0)	31.9 (31.0 to 32.8)
Adjusted hazard ratio (95% CI) ^b	0.90 (0.87 to 0.93)	1 [Reference]
Adjusted incident rate difference (95% CI) ^c		-3.2 (-4.1 to -2.2)

(continued)

Table 2. Rates and Adjusted Hazard Ratios for Major Adverse Cardiovascular Events (MACE) in Weighted Cohort (continued)

	Metformin	Sulfonylurea
Sensitivity Analysis: Excluding Medicare Advantage		
No. at risk in weighted cohort	20 909	21 015
Primary outcome: composite MACE	893	1195
Person-years	36 670	38 674
Unadjusted rate/1000 person-years (95% CI)	24.4 (22.8 to 26.0)	30.9 (29.2 to 32.7)
Adjusted hazard ratio (95% CI) ^b	0.80 (0.74 to 0.87)	1 [Reference]
Adjusted incident rate difference (95% CI) ^c	-6.2 (-8.0 to -4.0)	

Abbreviations: AMI, acute myocardial infarction; eGFR, estimated glomerular filtration rate; TIA, transient ischemic attack.


^a Primary analysis considers patients persistent with regimen until they do not have oral antidiabetic medications for 90 days.

^b Cox proportional hazards model for MACE, adjusted for demographics, clinical information derived from the electronic health record, comorbidities, use of medications, and health care utilization (see eTable 1 in the Supplement). All continuous variables were modeled as restricted cubic splines.

^c The decrease in the number of events per 1000 person-years of metformin use compared with sulfonylurea use among patients with reduced kidney function. The adjusted rate difference is estimated by multiplying the unadjusted incident rate for sulfonylurea by the adjusted hazard ratio minus 1. Confidence bounds are calculated using the respective bounds from the hazard ratio.

^d Patients remain in their exposure group, regardless of persistence with drug therapy, until outcome or end of the study.

Figure 3. Adjusted Hazard Ratios for Major Adverse Cardiovascular Events by Subgroups



FDA indicates Food and Drug Administration.

^a P value for eGFR prime term (it was modeled as a spline so there are multiple terms).

metformin can be safely used in patients with mild kidney function impairment (45-60 mL/min/1.73 m²) and some patients with moderate kidney function impairment (eGFR, 30-45 mL/min/1.73 m²).

At the same time, the FDA also recommended that kidney function be evaluated with eGFR rather than creatinine.³⁴ This US guidance is now more aligned with recommendations from the United Kingdom, Canada, and Australia, which emphasize metformin use based on eGFR criteria rather than creatinine because eGFR more accurately measures kidney function.^{35,36} Patients with reduced eGFR may use metformin with frequent monitoring and dose reduction, but metformin is contraindicated at an eGFR less than 30 mL/min/1.73 m².

The FDA decision about metformin was based in part on data from 2 comprehensive reviews. The systematic review by Inzucchi et al³⁷ included 65 studies (the largest had 10 000 patients) and found no increased risk of metformin-associated lactic acidosis in patients with mild to moderate kidney disease. The meta-analysis by Crowley and colleagues³² describes the existing evidence on metformin effectiveness in kidney disease. This meta-analysis included 6 studies (5 cohort studies and 1 nested case-control study) of patients with diabetes and chronic kidney disease. All the studies compared clinical outcomes between patients using metformin and non-metformin regimens, including multiple drugs. Five of the 6 studies (n = 33 442) examined all-cause mortality. The relative

risk of all-cause mortality was lower in patients taking metformin than for patients not taking metformin (HR, 0.78 [95% CI, 0.63-0.96]; $I^2 = 79.8\%$).

Only 2 of the 6 studies (n = 14 408) examined the association between diabetes treatments and MACE in patients with reduced kidney function. Both compared metformin vs non-metformin regimens. The first, by Ekström et al,³⁸ used a Swedish registry to define MACE as diagnosis of myocardial infarction, angina, hemorrhagic or ischemic stroke, peripheral vascular disease, or coronary disease procedure. They found no significant difference in MACE between metformin patients with eGFR of 45 to less than 60 mL/min/1.73 m² (n = 6655; HR, 0.94 [95% CI, 0.84-1.05]) and 30 to less than 45 mL/min/1.73 m² (n = 1894; HR, 1.00 [95% CI, 0.83-1.19]) compared with other regimens (including but not restricted to sulfonylureas). The second study was conducted in the United States by Masoudi et al³⁹ and examined heart failure readmission in patients with reduced kidney function. They demonstrated lower readmission risk (n = 5859; HR, 0.91 [95% CI, 0.84-0.99]) for metformin compared with sulfonylurea or insulin use. The current study adds to the body of evidence from these 2 prior studies by examining important cardiovascular outcomes (MACE) in a large population who persisted with their initial diabetes treatment once they reached reduced kidney function threshold.

Limitations

This study has several limitations. First, incident therapy persistence with either metformin or sulfonylureas at the kidney threshold was required and excluded many patients who discontinued, added, or switched to newer medications at or before reaching the kidney threshold. The study design also excluded those who began diabetes treatment after the onset of reduced kidney function. While reducing sample size, this design choice allowed the evaluation of those patients who continued taking their initial glucose-lowering monotherapy despite changing kidney function. Furthermore, a competing risk model was used to address concerns that nonpersistence with glucose-lowering medications or noncardiovascular death would preclude assessment of MACE outcomes. Findings from

this study cannot be generalized to patients who already have a reduced eGFR at the time of metformin initiation.

Second, veterans may not receive all their care at VHA facilities, and some MACE outcomes may have been missed despite the linkage to Medicare and Medicaid data.

Third, cohort entry and the start of follow-up was either an elevated serum creatinine or reduced eGFR less than 60 mL/min/1.73 m². It is possible that for some patients this kidney threshold may represent an acute kidney injury event rather than progression to chronic kidney disease. There was inadequate statistical power to evaluate differences in MACE events in patients with persistently reduced kidney function. The sensitivity analysis, which required a confirmatory reduced eGFR, found results consistent with the main findings but without statistical significance; therefore, overall results cannot be extrapolated to this group of patients.

Fourth, although propensity score weighting and direct covariate adjustment were used to address confounding, there is likely residual confounding.

Fifth, the study did not include a dose analysis or compare those who continued metformin use with those who switched to a newer agent to determine whether the findings were associated with specific doses of metformin or sulfonylurea or whether results were consistent when compared with a newer drug class.

Sixth, the study population was mostly elderly white men, and may not be representative of the larger population of patients with diabetes and reduced kidney function. This should be considered when generalizing the study results to other populations.

Seventh, it cannot be determined from these analyses whether metformin is associated with a reduced risk or sulfonylureas are associated with an increased risk of MACE outcomes.

Conclusions

Among patients with diabetes and reduced kidney function persisting with monotherapy, treatment with metformin, compared with a sulfonylurea, was associated with a lower risk of MACE.

ARTICLE INFORMATION

Accepted for Publication: August 9, 2019.

Published Online: September 19, 2019.
doi:10.1001/jama.2019.13206

Author Contributions: Drs Roumie and Hackstadt had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Roumie, Min, Hung, Greevy, Grijalva, Elasy, Griffin.

Acquisition, analysis, or interpretation of data: Roumie, Chipman, Hackstadt, Hung, Greevy, Grijalva, Elasy, Griffin.

Drafting of the manuscript: Roumie.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Chipman, Hackstadt, Hung, Greevy.

Obtained funding: Roumie.

Administrative, technical, or material support: Roumie, Hackstadt, Griffin.

Supervision: Roumie, Hung, Greevy, Grijalva, Elasy.

Conflict of Interest Disclosures: Dr Roumie reported receiving grants from the Veterans Health Administration (VHA), Patient-Centered Outcomes Research Institute, and the Agency for Healthcare Research and Quality. Dr Chipman reported receiving grants from the VHA, a TLI Scholar award from the National Institutes of Health (NIH), and a graduate student award from Vanderbilt University. Dr Hackstadt reported receiving grants from the VHA and the NIH. Dr Grijalva reported consultancies for Pfizer, Merck, and Sanofi; grants from Sanofi, the Centers for Disease Control and Prevention, the Agency for Healthcare Research and Quality, the NIH, and the Food and Drug Administration. Dr Griffin reported grants from the VHA, Food and Drug Administration, and Centers for Disease Control and Prevention. No other disclosures were reported.

Funding/Support: This study was funded by the VA Clinical Science Research and Development investigator-initiated grant CX000570-07

(Dr Roumie). Drs Roumie and Elasy were supported in part by the Center for Diabetes Translation Research (P30DK092986). Dr Min was supported by the VA Office of Academic Affiliations Quality Scholars Program. Dr Hung was supported by a VA Clinical Science Research and Development investigator-initiated grant (CX000982). Support for Veterans Affairs/Centers for Medicare & Medicaid Services data was provided by the Department of Veterans Affairs, Veterans Affairs Health Services Research and Development Service, and Veterans Affairs Information Resource Center (project No. SDR 02-237 and 98-004).

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The content of this article does not represent the views of the US Department of Veterans Affairs or the US government.

Data Sharing Statement: The protocol, statistical code, and deidentified and anonymized data set are available from Dr Roumie with a written request.

REFERENCES

- Geiss LS, Kirtland K, Lin J, et al. Changes in diagnosed diabetes, obesity, and physical inactivity prevalence in US counties, 2004-2012. *PLoS One*. 2017;12(3):e0173428. doi:10.1371/journal.pone.0173428
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*. 1998;352(9131):854-865. doi:10.1016/S0140-6736(98)07037-8
- Standards of medical care in diabetes 2017: summary of revisions. *Diabetes Care*. 2017;40(suppl 1):S4-S5. doi:10.2337/dc17-S003
- Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. *Ann Intern Med*. 2012;157(9):601-610. doi:10.7326/0003-4819-157-9-201211060-00003
- Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. *N Engl J Med*. 2008;359(15):1565-1576. doi:10.1056/NEJMoa0806359
- Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med*. 2008;359(15):1577-1589. doi:10.1056/NEJMoa0806470
- Azoulay L, Suissa S. Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. *Diabetes Care*. 2017;40(5):706-714. doi:10.2337/dc16-1943
- Food Drug Administration. Center for Drug Evaluation and Research application number: 20-357/s019: final printed label: Glucophage. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20357s019_Glucophage_prntlbl.pdf. Accessed January 5, 2015.
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*. 1998;352(9131):837-853. doi:10.1016/S0140-6736(98)07019-6
- Gerstein HC, Miller ME, Genuth S, et al; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. *N Engl J Med*. 2011;364(9):818-828. doi:10.1056/NEJMoa1006524
- Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med*. 2009;360(2):129-139. doi:10.1056/NEJMoa0808431
- Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008;358(24):2560-2572. doi:10.1056/NEJMoa0802987
- Humensky J, Carretta H, de Groot K, Brown MM, Tarlov E, Hynes DM. Service utilization of veterans dually eligible for VA and Medicare fee-for-service: 1999-2004. *Medicare Medicaid Res Rev*. 2012;2(3):mmrr.002.03.a06. doi:10.5600/mmrr.002.03.A06
- Hynes DM, Koelling K, Stroupe K, et al. Veterans' access to and use of Medicare and Veterans Affairs health care. *Med Care*. 2007;45(3):214-223. doi:10.1097/01.mlr.00000244657.90074.b7
- McCarthy JF, Valenstein M, Kim HM, Ilgen M, Zivin K, Blow FC. Suicide mortality among patients receiving care in the Veterans Health Administration health system. *Am J Epidemiol*. 2009;169(8):1033-1038. doi:10.1093/aje/kwp010
- Center of Excellence for Suicide Prevention. Joint Department of Veterans Affairs (VA) and Department of Defense (DoD) Suicide Data Repository: National Death Index (NDI). <http://vaw.virec.research.va.gov/Mortality/Overview.htm>. Accessed December 2018.
- Greevy RA Jr, Huizinga MM, Roumie CL, et al. Comparisons of persistence and durability among three oral antidiabetic therapies using electronic prescription-fill data: the impact of adherence requirements and stockpiling. *Clin Pharmacol Ther*. 2011;90(6):813-819. doi:10.1038/clpt.2011.228
- Niesner K, Murff HJ, Griffin MR, et al. Validation of VA administrative data algorithms for identifying cardiovascular disease hospitalization. *Epidemiology*. 2013;24(2):334-335. doi:10.1097/EDE.0b013e3182821e75
- Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. *Arch Gen Psychiatry*. 2001;58(12):1161-1167. doi:10.1001/archpsyc.58.12.1161
- Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604-612. doi:10.7326/0003-4819-150-9-200905050-00006
- Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. *JAMA*. 2014;311(24):2518-2531. doi:10.1001/jama.2014.6634
- Skali H, Uno H, Levey AS, Inker LA, Pfeffer MA, Solomon SD. Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. *Am Heart J*. 2011;162(3):548-554. doi:10.1016/j.ahj.2011.06.006
- vanBuuren S. *Flexible Imputation of Missing Data*. Boca Raton, FL: CRC Press/Taylor and Francis Group; 2012.
- D'Agostino R, Rubin D. Estimating and using propensity scores with partially missing data. *J Am Stat Assoc*. 2000;95(451):749-759. doi:10.1080/01621459.2000.10474263
- Franklin JM, Eddings W, Austin PC, Stuart EA, Schneeweiss S. Comparing the performance of propensity score methods in healthcare database studies with rare outcomes. *Stat Med*. 2017;36(12):1946-1963.
- Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. *Biometrika*. 1994;81:515-526. doi:10.1093/biomet/81.3.515
- Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. *Circulation*. 2016;133(6):601-609. doi:10.1161/CIRCULATIONAHA.115.017719
- Li J, Scheike TH, Zhang MJ. Checking Fine and Gray subdistribution hazards model with cumulative sums of residuals. *Lifetime Data Anal*. 2015;21(2):197-217. doi:10.1007/s10985-014-9313-9
- Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc*. 1999;94(466):496-509. doi:10.1080/01621459.1999.10474144
- Huizinga MM, Roumie CL, Elasy TA, et al. Changing incident diabetes regimens: a Veterans Administration cohort study from 2000 to 2005. *Diabetes Care*. 2007;30(8):e85. doi:10.2337/dc07-0650
- Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Griffin MR. Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study. *BMC Endocr Disord*. 2016;16(1):32. doi:10.1186/s12902-016-0101-2
- Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. *Ann Intern Med*. 2017;166(3):191-200. doi:10.7326/M16-1901
- Flory JH, Hennessy S. Metformin use reduction in mild to moderate renal impairment: possible inappropriate curbing of use based on food and drug administration contraindications. *JAMA Intern Med*. 2015;175(3):458-459. doi:10.1001/jamainternmed.2014.6936
- Food and Drug Administration. FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. <https://www.fda.gov/Drugs/oodDrugSafety/ucm493244.htm>. Published 2016. Accessed April 8, 2016.
- European Medications Agency. Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function. <https://www.ema.europa.eu/en/medicines/human/referrals/metformin-metformin-containing-medicines>. Accessed June 13, 2019.
- Diabetes Canada. *Canadian Journal of Diabetes*. <https://guidelines.diabetes.ca/docs/CPG-2018-full-EN.pdf>. Published April 2018. Accessed June 13, 2019.
- Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. *JAMA*. 2014;312(24):2668-2675. doi:10.1001/jama.2014.15298
- Ekström N, Schiöler L, Svensson AM, et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. *BMJ Open*. 2012;2(4):e001076. doi:10.1136/bmjopen-2012-001076
- Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. *Circulation*. 2005;111(5):583-590. doi:10.1161/01.CIR.0000154542.13412.B1